News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

First-line nivolumab-ipilimumab therapy extends survival in unresected HCC
25 Feb 2025
byStephen Padilla
Treatment with nivolumab plus ipilimumab in the frontline setting provides clinically meaningful overall survival (OS) benefit compared with lenvatinib or sorafenib to patients with unresectable hepatocellular carcinoma (HCC) who were naive to systemic therapy, according to data from the phase III CheckMate 9DW study presented at ASCO GI 2025.
First-line nivolumab-ipilimumab therapy extends survival in unresected HCC
25 Feb 2025
Is it safe to administer RSV vax with flu or COVID-19 vaccines in adults?
25 Feb 2025
byAudrey Abella
A two-part phase III study in adults aged ≥50 years supports the co-administration of the respiratory syncytial virus (RSV) vaccine, mRNA-1345, with the seasonal standard-dose quadrivalent inactivated influenza vaccine, SIIV4, or the bivalent COVID-19 vaccine, mRNA-1273.214.







